Farview

Farview (formerly known as VaccineLedger) leverages blockchain technology to revolutionize the supply chain of antimicrobial resistance (AMR) drugs, enhancing transparency, reducing waste, and ensuring equitable access. This platform mitigates AMR by optimizing drug distribution, ensuring medications are efficiently used and accessible to those most in need, particularly in LMICs.

Sid Chakravarthy, Founder and CEO of StaTwig, is our visionary leader. With extensive IT and supply chain expertise, he's dedicated to solving supply chain inefficiencies through innovative technology solutions.

StaTwig's Farview application is tackling the formidable challenge of antimicrobial resistance (AMR) supply chain failures. These failures include cold chain failures, counterfeit drugs, and the impact of climate change on drug efficacy. 

AMR poses a significant threat globally, with an estimated 10 million lives at risk annually by 2050 if current trends continue. In low- and middle-income countries, the situation is dire, with inefficient supply chains leading to drug shortages, misuse, and the proliferation of substandard and falsified medications.

Farview, proven and globally recognized open-source solution, employs blockchain technology for real-time tracking and traceability of AMR-related drugs, offering unprecedented supply chain visibility and data integrity. This approach directly addresses cold chain failures by monitoring storage conditions in real-time, ensuring drugs maintain their efficacy until they reach those in need. The application's capability to reduce the use of substandard and falsified antimicrobials is vital for preventing further development of drug-resistant bacterial strains.

Farview's integration of Gen AI to engage with beneficiaries and gather mobility data offers innovative ways to determine access to antibiotics and track the spread of AMR. This feature is crucial for tailoring interventions and ensuring that communities have the information and resources needed to combat AMR effectively.

Farview targets the critical need for efficient antimicrobial resistance (AMR) drug distribution in low- and middle-income countries (LMICs), serving vulnerable populations disproportionately affected by AMR. By leveraging blockchain and AI, Farview enhances supply chain transparency and integrity, ensuring equitable access to essential medications and reducing the risk of drug shortages, misuse, and overuse, which contribute to AMR.

Our platform specifically addresses the urgent needs of healthcare providers and patients in LMICs by optimizing drug distribution, mitigating stockouts, and minimizing wastage. This is particularly vital in combating the spread of resistant infections and advancing global health equity. Additionally, Farview's innovative technology plays a crucial role in reducing the use of substandard and falsified antimicrobials in both human healthcare and the food chain, directly impacting the quality of care and patient outcomes.

By providing real-time updates, Farview also informs stakeholders about the impact of climate change on bacterial AMR and antibiotic supply chains, enabling proactive adjustments and resilience in drug distribution networks.
Engagement with our target audience through continuous feedback loops ensures our solution remains aligned with their evolving needs, making Farview a pivotal tool in the global fight against AMR, enhancing healthcare delivery, and safeguarding public health.

Farview contributes to public good by directly aligning with SDG3 (Good Health and Well-being) and SDG12 (Responsible Consumption and Production) through its innovative supply chain solution. By enhancing the efficiency and transparency of distribution, Farview ensures broader and more equitable access to essential medicines, vaccines, directly impacting global health outcomes. This contribution to public health is a fundamental public good, ensuring that communities worldwide can benefit from improved availability and safety, thus supporting the goal of good health and well-being for all.

Moreover, by optimizing the supply chain, Farview addresses responsible consumption and production. It minimizes waste through better tracking and management of inventories, ensuring that resources are used efficiently and sustainably. This not only reduces environmental impact but also ensures that medicines, drugs, vaccines are used where they are most needed, promoting responsible stewardship of global health resources.

As an open-source platform recognized and funded by UNICEF, Farview offers a scalable, free-to-use solution that can be adapted and adopted globally, making its benefits universally available and supporting the ethos of providing a public good. Through its innovative approach and commitment to equity, Farview exemplifies how technology can be harnessed to serve the global community, fulfilling essential public health needs.

Inputs - The process begins with capturing detailed stock information of AMR medicines across central and regional levels using both mobile and web applications, ensuring comprehensive data collection.

Activities - Store personnel at various levels will input stock movements, while frontline workers capture essential cold chain data. This meticulous tracking includes monitoring near-expiry product details, with automated alerts to relevant personnel about critical stock information.

Output - The immediate result is real-time access to stock positions and cold chain data across locations, enabling visibility of stock movements and expiration alerts, this supports robust reporting and analysis for strategic decision-making.

Outcome - The system leads to reduced wastage of critical AMR stocks, optimization of inventory levels, and enhanced tracking capabilities. By ensuring the right medicines are available where and when needed.

Impact - The overarching impact is a marked improvement in the quality of life for individuals, especially those in vulnerable communities who historically suffer from inadequate access to essential medications. By addressing key logistical challenges in the AMR medicine supply chain, Farview facilitates more effective treatment regimes.

Evidence - Results from our pilot in Costa Rica, where Farview's implementation led to a measurable decrease in stock wastage and improved availability of essential medicines and beneficiary tracking. 

In the next year, Farview aims to consolidate its impact against Antimicrobial Resistance (AMR) by enhancing its presence in Bangladesh and expanding to three additional countries. Leveraging our UNICEF partnership and successes in pilot regions, we'll incorporate AI and blockchain to boost data accuracy and transparency, vital for AMR management. Our strategy includes forging alliances with health ministries and global health bodies to facilitate Farview's integration into national health systems.

Over the following two years, our ambition is to extend Farview's reach to 10 countries, particularly those facing high AMR threats. This will involve cultivating local partnerships, rolling out training for healthcare workers, and syncing with national health information systems to embed Farview in AMR containment strategies. Continuous platform refinement, informed by user feedback, will ensure Farview's adaptability and user-friendliness across diverse health environments.

Our goal is to position Farview as a cornerstone in the global fight against AMR, contributing to sustainable healthcare improvements and better outcomes worldwide by enhancing antibiotic stewardship and curtailing misuse.

To gauge Farview's impact and scalability in combating Antimicrobial Resistance (AMR) and enhancing healthcare supply chain management, we deploy a targeted set of Key Performance Indicators (KPIs) tailored to the unique requirements of each deployment country.

1. Expansion and Adoption - We measure our growth through the number of countries and users adopting Farview, utilizing platform registration and user account data to capture our geographic and demographic reach.

2. Supply Chain Visibility - The depth of our impact is assessed by tracking the number of units monitored at each stakeholder level, offering unparalleled visibility and control over the supply chain.

3. Wastage Reduction - By quantifying units saved from nearing expiration, we highlight our contribution to minimizing waste and maximizing resource utilization.

4. Cold Chain Integrity - Tracking cold chain failures through system alerts and incident reports, we ensure the integrity of sensitive medical supplies, safeguarding their efficacy.

5. Delivery Success - Our platform's efficiency is reflected in the number of shipments successfully delivered, a direct indicator of our operational success and reliability.

6. Direct Impact on Beneficiaries - Most critically, we monitor the number of beneficiaries receiving supplies, emphasizing our role in improving healthcare access and outcomes.

1. Political and Geo-Political Risks - Changing governments or geopolitical tensions can disrupt regulatory and policy landscapes, challenging Farview's deployment.
Mitigation - Building robust relationships with health ministries and global organizations to adapt to policy shifts, ensuring our operations align with governmental healthcare objectives.

2. Resistance to Technology Change - Traditional practices may hinder the adoption of new technologies.
Mitigation - Implementing comprehensive stakeholder engagement and training programs to demonstrate Farview's benefits, enhancing user experience to facilitate transition.

3. Continuous Funding Dependency is a challenge for the sustained operation and expansion of Farview.
Mitigation - We plan to diversify funding through international partnerships, public-private collaborations, and revenue opportunities, reducing reliance on a single source. Recognizing that implementation needs vary by country, we will customize Farview to local requirements, ensuring tailored maintenance and support, thereby enhancing our financial stability and adaptability.

4. Procurement Delays - Bureaucratic procurement processes can slow Farview's deployment.
Mitigation - Streamlining procurement with health ministries via effective communication and clear documentation of Farview's value.

Our strategy focuses on proactive risk management and leveraging partnerships to ensure Farview's sustainable growth and impact, addressing barriers through strategic planning and stakeholder collaboration.

We are applying to The Trinity Challenge because it aligns with our mission to leverage digital innovation for enhancing global health outcomes. Our solution, designed to address supply chain inefficiencies in healthcare, can significantly benefit from the Challenge's support in overcoming two main barriers: scalability and collaborative networks.

First, scalability is a challenge due to the complex nature of global healthcare supply chains, which vary significantly across regions. The Trinity Challenge can provide both the financial resources and the expertise needed to customize our solution to different countries' specific needs, ensuring that our technology can be adapted and scaled efficiently worldwide.

Second, establishing a global network of partners is crucial for our solution's success. The Trinity Challenge offers access to a unique ecosystem of public and private sector organizations. This network can help us forge strategic partnerships, enhance our solution's credibility, and expand its reach to have a broader impact on global health security.

By addressing these barriers, The Trinity Challenge can help us accelerate our solution's deployment, making a meaningful difference in preventing, detecting, and responding to health emergencies globally.

• Ministry of Health in various countries - Partnering with national health ministries would enable direct integration of Farview into public health strategies, ensuring alignment with local AMR containment efforts.

• USAID - Collaboration with USAID can provide access to extensive networks and resources for deploying Farview in LMICs, where AMR is a pressing issue.

• World Health Organization (WHO) - Engaging with WHO would align Farview with global health standards and practices.

• National Health Authority (NHA) India - Partnering with NHA India can facilitate Farview's integration into India's digital health ecosystem, addressing AMR challenges in one of the world's most populous countries.

• Food and Agriculture Organization (FAO) - Collaboration with FAO would strengthen Farview's application in the food supply chain.

• Global Fund - Partnering with the Global Fund can accelerate Farview's deployment in combating AMR through improved access to essential medicines.

• Innovate UK - Collaboration with Innovate UK can provide funding and support for technological innovation, enhancing Farview's capabilities.

These collaborations would provide invaluable support in scaling Farview, enhancing our understanding of supply chain challenges, and equipping our system to more effectively combat AMR globally.